Sanofi and GSK in advanced talks with European Union to provide up to 300 million doses of COVID-19 vaccine

  • The discussion focuses on the recombinant protein technology developed by Sanofi and on an adjuvant for pandemic use developed by GSK.
  • The two companies are committed to making their vaccine against Covid-19 available at an affordable price, anywhere in the world.


PARIS and LONDON – July 31, 2020 – Sanofi and GSK have entered into discussions with the European Commission (EC) for the supply of up to 300 million doses of a COVID-19 vaccine. The Commission has agreed to put in place a contractual framework for purchasing vaccine doses once the vaccine has been proven safe and effective, on behalf of all EU Member States. The vaccine candidate, developed by Sanofi in partnership with GSK, is based on the recombinant protein technology that Sanofi used to produce an influenza vaccine and on the adjuvant for pandemic use developed by GSK. The doses would be produced in European countries and in particular in France, Belgium, Germany and Italy. These discussions are an important milestone in the initiatives undertaken to protect the European population against Covid-19 and meet their needs.

« Today’s announcement ensures that millions of Europeans will have access to a potential vaccine to protect them against COVID-19, once its safety and effectiveness have been demonstrated. We have always been committed to providing an affordable vaccine that is accessible to all and are grateful to the European Commission for their continued engagement with us and their support. », declared Thomas Triomphe, Executive Vice-President and Global Head of Sanofi Pasteur. « With GSK, we are working tirelessly to develop and produce a vaccine to address this global health crisis. »

“GSK is proud to work in partnership with Sanofi to make this vaccine available to the European population as soon as possible. Our two companies have significant R&D and manufacturing capacities in Europe and are already working to increase the production capacities of their respective networks. The announcement of the EC reinforces the efforts we are making to this end ”, added Roger Connor, President of GSK Vaccines.

Sanofi is leading the clinical development and vaccine registration procedures and plans to begin a Phase I / II study in September, followed by a Phase III study by the end of 2020. If the data is positive, regulatory approval for this vaccine could be obtained in the first half of 2021. At the same time, Sanofi and GSK are increasing their antigen and adjuvant production capacities to be able to manufacture up to one billion doses per year in total.

Sanofi and GSK commit to making this vaccine available to everyone

Sanofi and GSK recently signed agreements with the United States, where they forged lasting partnerships with the Biomedical Advanced Research and Development Authority (BARDA, Authority for Advanced Biomedical Research and Development), as well as with the UK government. In 2021-2022, the two partners also plan to make a significant portion of their total production available to the global Access to COVID-19 Tools (ACT) Accelerator initiative, an international collaboration of heads of government and executives. international health organizations, companies and charities to accelerate the development, production and equitable access to tests for COVID-19, as well as to treatments and vaccines against this disease.

On the front lines of the fight against COVID-19

In addition to the development of a recombinant protein vaccine in collaboration with GSK, Sanofi is also developing a candidate-messenger RNA vaccine in partnership with Tranhooly-news.com Bio. Of all the multiple innovative vaccine development platforms currently being tested by the pharmaceutical industry, the mRNA platform is considered to be one of the most promising. Sanofi plans to start a Phase I study by the end of the year and, if its data is positive, to get approval for its vaccine sooner in the second half of 2021. Tranhooly-news.com Bio builds the necessary mRNA production capacity and Sanofi expects to be able to deliver between 90 and 360 million doses per year.

About GSK

A major player in the global pharmaceutical industry, focused on scientific research, GSK’s mission is to improve the quality of life so that every human being is more active, feels better and lives longer. GSK is one of the world’s leading vaccine manufacturers. For more information, see the website www.gsk.com.

About Sanofi

Sanofi’s vocation is to support those facing health problems. A global biopharmaceutical company specializing in human health, we prevent disease with our vaccines and offer innovative treatments. We support both those suffering from rare diseases and the millions of people suffering from a chronic disease.

Sanofi and its more than 100,000 employees in 100 countries transform scientific innovation into healthcare solutions around the world.

Sanofi, Empowering Life, giving full force to life.


Media Relations
Ashleigh Koss
Tel.: +1 908-981-8745
Ashleigh.Koss@sanofi.com

Jean-Baptiste Froville
Phone. : +33 (0) 1 53 77 46 46
mr@sanofi.com


Investor Relations
Eva Schaefer-Jansen
Phone. : +33 (0) 1 53 77 45 45
ir@sanofi.com
Forward-looking statements
This press release contains forward-looking statements. These statements do not constitute historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements relating to plans, objectives, intentions and expectations regarding future financial results, events, operations, services, product development and their potential or future performance. These forward-looking statements can often be identified by the words “expect”, “anticipate”, “believe”, “intend”, “estimate” or “plan” and by other similar terms. Although Sanofi management believes that these forward-looking statements are reasonable, investors are alerted to the fact that these forward-looking statements are subject to numerous risks and uncertainties, which are difficult to predict and generally beyond Sanofi’s control, which may imply that the actual results and events achieved differ significantly from those expressed, inferred or expected in the forward-looking information and statements. These risks and uncertainties include in particular the uncertainties inherent in research and development, future clinical data and analyzes, including post-marketing, decisions of regulatory authorities, such as the FDA or the EMA, to approve or not, and on what date, of the drug, process or biologic filing application for one of these product candidates, as well as their decisions on labeling and other factors which may affect the availability or commercial potential of these product candidates, the fact that product candidates if approved may not meet with commercial success, the future approval and commercial success of therapeutic alternatives, the ability to Sanofi to seize opportunities for external growth and to finalize the related transactions, the evolution of exchange rates and interest rates, the instability of economic and market conditions é,, cost control initiatives and their evolution, the impact that COVID-19 will have on Sanofi, its customers, suppliers and partners and their financial situation, as well as on its employees and on the global economy. Any significant impact on these could negatively impact Sanofi. The situation is changing rapidly and other consequences that we do not know could emerge and exacerbate the risks previously identified. These risks and uncertainties also include those that are developed or identified in public documents filed by Sanofi with the AMF and the SEC, including those listed in the “Risk Factors” and “Forward-Looking Statements” sections of the Document d ‘. 2019 Sanofi universal registration, which has been filed with the AMF as well as in the “Risk Factors” and “Cautionary Statement Concerning Forward-Looking Statements” sections of the 2019 Sanofi Annual Report on Form 20-F, which has been filed with the SEC. Sanofi makes no commitment to update forward-looking information and statements, subject to applicable regulations, in particular Articles 223-1 et seq. Of the general regulations of the Autorité des marchés financiers.

Attachment